A Sturani, E Degli Esposti, A De March, A Santoro, G Fuschini, A Zuccalà, C Chiarini, C Flamigni, P Zucchelli
{"title":"Dopaminergic control of sympathetic activity and blood pressure in haemodialysis patients.","authors":"A Sturani, E Degli Esposti, A De March, A Santoro, G Fuschini, A Zuccalà, C Chiarini, C Flamigni, P Zucchelli","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Bromocriptine was used to test the hypothesis that the abnormality of the dopaminergic system described in haemodialysis patients may cause enhanced sympathetic activity and high blood pressure. Bromocriptine significantly reduced supine mean blood pressure and plasma noradrenaline. Moreover, although the increments in plasma noradrenaline during tilt tests were reduced by bromocriptine there was a significant improvement in the response of blood pressure. These results suggest that dopaminergic control of sympathetic activity may be impaired in haemodialysis patients and may be a cause of high blood pressure. Moreover, a restoration of a normal relationship between noradrenaline and adrenergic receptors would be consistent with the present results.</p>","PeriodicalId":76354,"journal":{"name":"Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association","volume":"20 ","pages":"156-60"},"PeriodicalIF":0.0000,"publicationDate":"1983-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Bromocriptine was used to test the hypothesis that the abnormality of the dopaminergic system described in haemodialysis patients may cause enhanced sympathetic activity and high blood pressure. Bromocriptine significantly reduced supine mean blood pressure and plasma noradrenaline. Moreover, although the increments in plasma noradrenaline during tilt tests were reduced by bromocriptine there was a significant improvement in the response of blood pressure. These results suggest that dopaminergic control of sympathetic activity may be impaired in haemodialysis patients and may be a cause of high blood pressure. Moreover, a restoration of a normal relationship between noradrenaline and adrenergic receptors would be consistent with the present results.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
